Skip to content
PIP-2403-3.jpg

Image -

PIP-2403-3.jpg

Den innhentede kapitalen skal ifølge Pila Pharma brukes til å undersøke sikkerheten ved molekylet når doseringen økes, samt til å utvide studiens størrelse, slik at man kan bruke empiriske statistiske beregninger til å avgjøre om det er potensial for et nytt legemiddel i tablettform til behandling av fedme. Foto: Pila Pharma.
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
File format:
.jpg
Size:
2886 x 2200, 2.94 MB
Download

Related content

Welcome to Epicent Public Relations A/S!

Epicent was founded in 1999 and specializes in press assignments. For five consecutive years, we have been named among Denmark’s fastest growing companies.

Boasting extensive experience in increasing brand awareness, we apply our knowhow and strong editorial networks to ensure optimal execution of PR strategies and multiply clients’ exposure in editorial media. Locally, regionally, nationally and internationally.

Epicent Public Relations A/S

Gåseagervej 12 E
8250 Egå
Denmark

Visit our other newsrooms